New employees at Eli Lilly and Co. get a letter encouraging them to join one of the pharmaceutical firm’s affinity groups. There’s one for African Americans, one for Latino employees—and four for Asians.
Indianapolis-based Lilly is working with advisers to gauge interest in selling off a selection of older drugs for antibiotics and central nervous system diseases in China.
Lilly’s revenue in the United States rose 11 percent year-over-year, to $3.4 billion, thanks largely to rising sales of diabetes drugs Trulicity and Basgalar, cancer treatment Verzenio and psoriasis medication Taltz.
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
One year ago, Indiana-based Endocyte Inc. bought the rights to a prostate cancer treatment for $12 million, plus future considerations. On Thursday, Novartis AG agreed to pay almost 200 times that amount to acquire Endocyte and the experimental therapy.
The standalone, two-story facility is expected to offer a wide array of inpatient and outpatient services, including addiction treatment, counseling and psychiatric intensive care.
Shares in Elanco Animal Health Inc. slipped as much as 3.3 percent Monday morning after lead managers and other banks involved in its recent initial public offering started coverage on the animal health company.
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
The owner of the 40,000-square-foot gym says upgrading the facility would cost tens of millions of dollars, and that the cost to maintain it is greater than the property’s value.
Eli Lilly and Co. received clearance Thursday from U.S. regulators for a new migraine drug that will be the third in a promising class of therapies for patients who suffer from the recurrent, painful headaches.
Greenfield-based Elanco Animal Health Inc. raised more than expected in its initial public offering, pricing its shares above the marketed price range.
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
The Indianapolis medical-software firm recently raised $10 million in venture funding and is launching two major products in one month.
The Greenfield-based animal health unit is gearing up for independence after 65 years as part of drugmaker Eli Lilly and Co. But Elanco has been struggling, and top management will have to work hard to stabilize the operation.
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
Elanco Animal Health Inc. could see a market value of as much as $20 billion, according to Bloomberg Intelligence. At that valuation, a share sale could raise as much as $5 billion.
